株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

瘍性大腸炎:KOLの洞察

Ulcerative Colitis: KOL Insight

発行 FirstWord 商品コード 320356
出版日 ページ情報 英文
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。
Back to Top
瘍性大腸炎:KOLの洞察 Ulcerative Colitis: KOL Insight
出版日: 2016年09月01日 ページ情報: 英文
概要

当レポートでは、北米および欧州の主要なKOL(キーオピニオンリーダー)12人の瘍性大腸炎に関する現在の治療選択肢および彼らの意思決定に影響を及ぼす競合する臨床的・コスト的な有益性についての見解を示しています。

軽度から中度のUC(瘍性大腸炎)の治療法

  • 市販薬
    • Uceris, Cortiment (Budesonide MMX; Cosmo/Santarus/Ferring)
  • パイプライン薬
    • LT 02 (放出制御ホスファチジルコリン; Lipid Therapeutics/Dr Falk Pharma/Nestle Health Science)

中度から重度のUC(瘍性大腸炎)

  • 市販薬
    • TNF阻害剤
      • Remicade (Infliximab; Janssen Biotech/Merck & Co. /田辺三菱製薬)
      • Humira (Adalimumab; AbbVie/エーザイ)
      • Simponi
    • TNK阻害剤のバイオシミラー
      • Remsima (Infliximab; Celltrion)
      • Inflectra (Infliximab; Hospira)
    • その他
      • Entyvio (vedolizumab; Millennium/武田薬品工業)
  • パイプライン薬
    • Etrolizumab (RG 7413, rhuMab beta7; Roche)
    • AJM 300 (Ajinomoto/Kissei)
    • Tofacitinib (CP 690550; Pfizer)
    • Ozanimod (RPC 1063; Celgene)
    • Kappaproct (cobitolimod, DIMS 0150; InDex Pharmaceuticals)
    • Alicaforsen (ISIS 2302; Atlantic Healthcare/Isis Pharmaceuticals)

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: 596200640

Are UC biosimilars a real or perceived threat to branded drugs?

Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; first-mover, Entyvio has a direct competitor coming on stream; and there is even talk of combination therapies and natural treatments in some quarters. What are the most influential key opinion leaders (KOLs) saying about market dynamics for UC drug therapies? How do they expect the market to flex and adapt? Are the new arrivals likely to face an enthusiastic welcome or more of a tepid reception?

Covering 5 marketed drugs and 9 pipeline therapies, this report gives the viewpoint from 12 KOLs in North America and Europe. Find out what they think about prescribing trends for different patient segments, the various products coming through the pipeline, and the key issues influencing treatment choices.

Top Takeaways

“Fundamentally biosimilars are going to be a good thing, because it's going to drive costs down. There might be some minor differences clinically, but improving access of these drugs to the population far outweighs any clinical downside or scientific downside.” US Key Opinion Leader.

Sample of brands covered:

  • Uceris/Cortiment (budesonide MMX; Cosmo/Santarus/Ferring)
  • Entyvio (vedolizumab; Takeda)
  • Etrolizumab (RG 7413, rhuMab beta7; Roche)
  • Stelara (ustekinumab; Johnson & Johnson)
  • Plus 10 more

Sample of KOLS interviewed

  • Dr. Adam Cheifetz, MD, Director of the Center for Inflammatory Bowel Disease at Beth Israel Deaconess Medical Center and Associate Professor of Medicine at Harvard Medical School.
  • Prof Jean-Frédéric Colombel, MD, Professor of Medicine and Director of the Susan and Leonor Feinstein IBD Center at Icahn School of Medicine in New York, NY.
  • Prof Gerhard Rogler, MD, PhD, Professor of Gastroenterology and Hepatology and Ordinarius ad personam at the University of Zürich, based at the University hospital of Zurich.
  • Prof Laurent Peyrin-Biroulet, MD, PhD, Department of HepatoGastroenterology, University Hospital of Nancy, Vandoeuvre-les-Nancy, France.
  • Plus 8 more - download the full list now >

Top Takeaways

  • Possible change to mild-to-moderate UC treatment: What difference will LT 02 (controlled-release phosphatidylcholine) make to entrenched 5-ASA prescribing habits? Do KOLs see LT 02 as an alternative or an add-on for early stage patients?
  • One brand is still the preferred TNF inhibitor, but for how long? How do gastroenterologists feel about switching to biosimilars and are they 100% confident about efficacy? Should originators be concerned for their market share?
  • Patient education: Is patient perception that non-branded drugs are inferior a real problem or a perceived one? Do KOLs believe pharma is helping or hindering patient views on biosimilars? Could (and should) more be done to educate patients about treatment choices?
  • Views on a crowded moderate-to-severe drug pipeline: One trial has recently halted but with 8 more still actively progressing, which hold most promise for KOLs? Conversely, which head-to-head trial is viewed as ‘risky' and which current study is described as ‘completely uninteresting'?
  • Two in-trial drugs are prompting more excitement than the rest: Which two potential new arrivals are viewed positively, but for different reasons? Could these be game changers for the severe patient segment?
  • Safety and cost dominate the debate: KOLs express cynicism about various pipeline drugs and possible treatment pathways, primarily due to side effect profiles and cost. The latter may also impact appetite for combination therapies, even though many KOLs are calling for this.
Back to Top